The invention relates to compounds of general formula I: ##STR00001## wherein R.sup.1, R.sup.2 and R.sup.3 are as defined in the description such compounds are metabotropic glutamate receptor antagonists and are useful in the treatment or prevention of mGluR5 receptor mediated disorders.